JP2010508262A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010508262A5 JP2010508262A5 JP2009533985A JP2009533985A JP2010508262A5 JP 2010508262 A5 JP2010508262 A5 JP 2010508262A5 JP 2009533985 A JP2009533985 A JP 2009533985A JP 2009533985 A JP2009533985 A JP 2009533985A JP 2010508262 A5 JP2010508262 A5 JP 2010508262A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- lipid
- composition according
- lipid composition
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 98
- 150000002632 lipids Chemical class 0.000 claims 96
- -1 lipid compound Chemical group 0.000 claims 42
- 150000001875 compounds Chemical class 0.000 claims 34
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 21
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 17
- 238000004519 manufacturing process Methods 0.000 claims 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 8
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000003282 alkyl amino group Chemical group 0.000 claims 7
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 7
- 125000004414 alkyl thio group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 4
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 4
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 4
- 125000000524 functional group Chemical group 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 150000007942 carboxylates Chemical class 0.000 claims 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000004014 thioethyl group Chemical group [H]SC([H])([H])C([H])([H])* 0.000 claims 3
- 125000004055 thiomethyl group Chemical group [H]SC([H])([H])* 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 claims 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010033307 Overweight Diseases 0.000 claims 2
- 102000023984 PPAR alpha Human genes 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 claims 2
- 150000003857 carboxamides Chemical class 0.000 claims 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims 2
- 230000001258 dyslipidemic effect Effects 0.000 claims 2
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 229960003194 meglumine Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 claims 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 claims 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims 1
- 125000006041 3-hexenyl group Chemical group 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- 206010014486 Elevated triglycerides Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 108010069201 VLDL Cholesterol Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 235000013793 astaxanthin Nutrition 0.000 claims 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims 1
- 229940022405 astaxanthin Drugs 0.000 claims 1
- 239000001168 astaxanthin Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 claims 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- 235000021323 fish oil Nutrition 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 229940106134 krill oil Drugs 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- KERBAAIBDHEFDD-UHFFFAOYSA-N n-ethylformamide Chemical compound CCNC=O KERBAAIBDHEFDD-UHFFFAOYSA-N 0.000 claims 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 235000019198 oils Nutrition 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 150000003858 primary carboxamides Chemical class 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000004035 thiopropyl group Chemical group [H]SC([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 125000002640 tocopherol group Chemical group 0.000 claims 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85573306P | 2006-11-01 | 2006-11-01 | |
| SE0602310 | 2006-11-01 | ||
| US85626706P | 2006-11-03 | 2006-11-03 | |
| US85626806P | 2006-11-03 | 2006-11-03 | |
| US85626906P | 2006-11-03 | 2006-11-03 | |
| SE0602352 | 2006-11-03 | ||
| PCT/IB2007/004613 WO2008142482A2 (en) | 2006-11-01 | 2007-11-01 | Omega-3 lipid compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010508262A JP2010508262A (ja) | 2010-03-18 |
| JP2010508262A5 true JP2010508262A5 (enExample) | 2010-12-16 |
Family
ID=42790506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009533985A Pending JP2010508262A (ja) | 2006-11-01 | 2007-11-01 | 組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110166228A1 (enExample) |
| EP (1) | EP2102139A2 (enExample) |
| JP (1) | JP2010508262A (enExample) |
| BR (1) | BRPI0717883A2 (enExample) |
| RU (2) | RU2509071C2 (enExample) |
| WO (1) | WO2008142482A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1888727B1 (en) | 2005-05-04 | 2015-04-15 | Pronova BioPharma Norge AS | New dha derivatives and their use as medicaments |
| WO2008132552A2 (en) * | 2006-11-01 | 2008-11-06 | Pronova Biopharma Norge As | Omega-3 lipid compounds |
| CN101535238A (zh) * | 2006-11-01 | 2009-09-16 | 普罗诺瓦生物医药挪威公司 | 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质 |
| WO2009056983A1 (en) * | 2007-10-31 | 2009-05-07 | Pronova Biopharma Norge As | New dha derivatives and their use as medicaments |
| CA3083698A1 (en) | 2008-03-26 | 2009-10-01 | Oramed Ltd. | Methods and compositions comprising serpin(s) for oral administration of protein |
| ES2345241B1 (es) | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
| AU2009354456B2 (en) | 2009-10-30 | 2014-05-08 | Tharos Ltd | Solvent-free process for obtaining phospholipids and neutral enriched krill oils |
| WO2013149384A1 (en) * | 2012-04-05 | 2013-10-10 | Nippon Suisan Kaisha, Ltd. | Brain atrophy prevention agent |
| EP3378472A1 (en) | 2012-08-09 | 2018-09-26 | Dynamis Therapeutics, Inc. | Combinations of meglumine |
| WO2014106846A2 (en) | 2013-01-03 | 2014-07-10 | Oramed Ltd. | Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof |
| EP2826384A1 (de) | 2013-07-16 | 2015-01-21 | Evonik Industries AG | Verfahren zur Trocknung von Biomasse |
| US9505709B2 (en) | 2014-05-05 | 2016-11-29 | Thetis Pharmaceuticals Llc | Compositions and methods relating to ionic salts of peptides |
| CN107075540A (zh) | 2014-10-02 | 2017-08-18 | 赢创德固赛有限公司 | 用于制备具有高细胞稳定性的含pufa生物质的方法 |
| DK3200606T3 (da) | 2014-10-02 | 2021-06-21 | Evonik Operations Gmbh | Fremgangsmåde til fremstilling af et fodermiddel, der indeholder pufa'er, ved ekstrusion af en biomasse, der indeholder pufa'er, af typen labyrinthulomycetes |
| BR112017006833B1 (pt) | 2014-10-02 | 2022-09-13 | Evonik Operations Gmbh | Alimento para animais contendo ácido graxo poli-insaturado e processo para produzir o mesmo |
| ES2900848T5 (en) | 2014-10-02 | 2025-09-25 | Evonik Operations Gmbh | Method for preparing an animal feed |
| WO2016086114A1 (en) * | 2014-11-25 | 2016-06-02 | Artdem, Llc | Sports drink formulation |
| WO2016207734A1 (en) * | 2015-06-26 | 2016-12-29 | Pronova Biopharma Norge As | Composition for treatment of nafld |
| HUE062513T2 (hu) * | 2015-07-22 | 2023-11-28 | Omeicos Therapeutics Gmbh | CYP-eikozanoidok metabolikusan robosztus analógjai szívbetegségek kezelésére |
| GB201521085D0 (en) * | 2015-11-30 | 2016-01-13 | Biozep As | Use |
| WO2022049168A1 (en) * | 2020-09-04 | 2022-03-10 | Dsm Ip Assets B.V. | 17(s)-hdpa for metabolic-syndrome related disorders |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2836628A (en) * | 1955-10-17 | 1958-05-27 | Monsanto Chemicals | Unsaturated branched-chain alcohols and methods of preparing same |
| SU523073A1 (ru) * | 1975-03-31 | 1976-07-30 | Всесоюзный научно-исследовательский институт синтетических и натуральных душистых веществ | Алкил-(алкенил)-замещенные 2,2диалкилпентен-4-ола, как душистые вещества в парфюмерных композици х и отдушках |
| US4132719A (en) * | 1978-04-20 | 1979-01-02 | Mcneilab Inc. | Dibromoalkylglycidic acid derivatives |
| US4264517A (en) * | 1978-12-11 | 1981-04-28 | G.D. Searle & Co. | Alkylphenyl 5Z,8Z,11Z,14Z,17Z-eicosapentaenoates |
| US4647685A (en) * | 1985-04-25 | 1987-03-03 | Eli Lilly And Company | 2-alkoxy-1-((2-trialkylaminoethoxy)phosphinyloxy)-alkenes and alkynes, hydroxy inner salts |
| GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| ITMI20012384A1 (it) | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
| CA2485116C (en) | 2002-05-03 | 2013-02-05 | Pronova Biocare As | Use of epa and dha in secondary prevention |
| AU2003252324A1 (en) * | 2002-08-07 | 2004-03-11 | Kao Corporation | Fat composition |
| EP1596853A1 (en) * | 2003-02-12 | 2005-11-23 | Galderma Research & Development, S.N.C. | Compounds which are modulators of the ppar-type receptors and their use in cosmetic or pharmaceutical compositions |
| WO2004078166A2 (en) * | 2003-03-05 | 2004-09-16 | Solvay Pharmaceuticals Gmbh | Use of omega-3-fatty acids in the treatment of diabetic patients |
| US20040235948A1 (en) * | 2003-03-05 | 2004-11-25 | Solvay Pharmaceuticals Gmbh | Treatment of diabetic patients with omega-3-fatty acids |
| JP4588984B2 (ja) * | 2003-07-31 | 2010-12-01 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 高度不飽和脂肪酸誘導体およびそれを含有する医薬組成物 |
| SE0303513D0 (sv) | 2003-12-19 | 2003-12-19 | Pronova Biocare As | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
| US20060135610A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
-
2007
- 2007-11-01 RU RU2009120534/04A patent/RU2509071C2/ru not_active IP Right Cessation
- 2007-11-01 EP EP07874033A patent/EP2102139A2/en not_active Withdrawn
- 2007-11-01 RU RU2009120568/04A patent/RU2009120568A/ru not_active Application Discontinuation
- 2007-11-01 JP JP2009533985A patent/JP2010508262A/ja active Pending
- 2007-11-01 BR BRPI0717883-2A patent/BRPI0717883A2/pt not_active IP Right Cessation
- 2007-11-01 WO PCT/IB2007/004613 patent/WO2008142482A2/en not_active Ceased
- 2007-11-01 US US12/446,249 patent/US20110166228A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010508262A5 (enExample) | ||
| RU2009120568A (ru) | Композиция | |
| JP2011528350A5 (enExample) | ||
| JP5337479B2 (ja) | 新規化合物 | |
| JP5843755B2 (ja) | 心血管性、代謝性および炎症性疾患領域に関する疾患の処置のための多価不飽和脂肪酸 | |
| CN101535238A (zh) | 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质 | |
| JP5552314B2 (ja) | 新規脂質化合物 | |
| JP7524411B2 (ja) | 硫黄を含有する構造的に強化された脂肪酸の非アルコール性脂肪性肝炎の予防及び／又は治療のための使用 | |
| JP2012526094A5 (enExample) | ||
| JP2011503057A5 (enExample) | ||
| JP2010509204A5 (enExample) | ||
| JP2011502113A5 (enExample) | ||
| KR20130132836A (ko) | 지질 화합물을 이용한 치료방법 | |
| US20100267828A1 (en) | dha derivatives and their use as medicaments | |
| JP5746730B2 (ja) | 新規化合物 | |
| RU2009120538A (ru) | Альфа-замещенные омега-3 липиды, которые являются активаторами или модуляторами рецептора, активируемого пролифераторами пероксисом (ppar) | |
| RU2007144347A (ru) | Производные докозагексаеновой кислоты и их применение в качестве лекарственных средств | |
| KR20200016613A (ko) | 새로운 ｄｈａ 유도체 및 약물로서 그들의 사용 | |
| HK1170722B (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas |